FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211672278> ?p ?o ?g. }

• W3211672278 endingPage "189" @default.
• W3211672278 startingPage "182" @default.
• W3211672278 abstract "Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have been the standard treatment for advanced EGFR-mutant adenocarcinoma, the effects of upfront EGFR-TKI use in unresectable stage III EGFR-mutant adenocarcinoma remain unexplored. Here, we conducted a retrospective study to compare different treatment strategies in these patients.From October 2010 to June 2019, patients with unresectable stage III adenocarcinoma who received treatment at a tertiary referral center were enrolled. Patients were classified into three groups: EGFR-mutant adenocarcinoma treated with concurrent chemoradiotherapy (group 1) or EGFR-TKI (group 2) and EGFR wild-type adenocarcinoma treated with concurrent chemoradiotherapy (group 3). Progression-free survival, progression-free survival-2, and overall survival were estimated and compared using Kaplan-Meier and log-rank tests.A total of 92 patients were enrolled; 10, 40, and 42 patients were assigned to groups 1, 2, and 3, respectively. Patients with EGFR mutations who received upfront EGFR-TKIs had significantly longer progression-free and overall survival than those who received upfront concurrent chemoradiotherapy (hazard ratio 0.33 vs. 0.34, p = 0.006 vs. 0.031) according to a Cox model adjusted for possible confounders. Moreover, upfront concurrent chemoradiotherapy did not lead to higher survival rates in patients with EGFR mutations than in those with EGFR wild-type adenocarcinoma (progression-free survival; hazard ratio 0.37, p = 0.036; overall survival; hazard ratio 0.35, p = 0.080) by Cox regression analysis.This current study suggests that EGFR-TKIs is a better choice for patients with unresectable stage III EGFR-mutant adenocarcinoma. However, further randomized studies are required to validate the results." @default.
• W3211672278 created "2021-11-22" @default.
• W3211672278 creator A5014155213 @default.
• W3211672278 creator A5020464501 @default.
• W3211672278 creator A5020831161 @default.
• W3211672278 creator A5028823803 @default.
• W3211672278 creator A5043529705 @default.
• W3211672278 creator A5046508238 @default.
• W3211672278 creator A5056645290 @default.
• W3211672278 creator A5059929672 @default.
• W3211672278 creator A5060246976 @default.
• W3211672278 creator A5071091495 @default.
• W3211672278 creator A5072180771 @default.
• W3211672278 date "2021-11-20" @default.
• W3211672278 modified "2023-10-16" @default.
• W3211672278 title "Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR ‐tyrosine kinase inhibitors" @default.
• W3211672278 cites W2012721144 @default.
• W3211672278 cites W2017813339 @default.
• W3211672278 cites W2061136476 @default.
• W3211672278 cites W2104701073 @default.
• W3211672278 cites W2118397697 @default.
• W3211672278 cites W2132870547 @default.
• W3211672278 cites W2144208206 @default.
• W3211672278 cites W2153169173 @default.
• W3211672278 cites W2153865661 @default.
• W3211672278 cites W2160889088 @default.
• W3211672278 cites W2222151010 @default.
• W3211672278 cites W2607954371 @default.
• W3211672278 cites W2620117724 @default.
• W3211672278 cites W2751913107 @default.
• W3211672278 cites W2753065806 @default.
• W3211672278 cites W2768989095 @default.
• W3211672278 cites W2770828094 @default.
• W3211672278 cites W2806325305 @default.
• W3211672278 cites W2809352131 @default.
• W3211672278 cites W2887416920 @default.
• W3211672278 cites W2888297236 @default.
• W3211672278 cites W2888877308 @default.
• W3211672278 cites W2889156470 @default.
• W3211672278 cites W2901105904 @default.
• W3211672278 cites W2920467130 @default.
• W3211672278 cites W2990041408 @default.
• W3211672278 cites W3087210493 @default.
• W3211672278 cites W3108819942 @default.
• W3211672278 cites W3127505349 @default.
• W3211672278 cites W3131416308 @default.
• W3211672278 cites W3139177891 @default.
• W3211672278 doi "https://doi.org/10.1111/1759-7714.14237" @default.
• W3211672278 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34799993" @default.
• W3211672278 hasPublicationYear "2021" @default.
• W3211672278 type Work @default.
• W3211672278 sameAs 3211672278 @default.
• W3211672278 citedByCount "1" @default.
• W3211672278 countsByYear W32116722782022 @default.
• W3211672278 crossrefType "journal-article" @default.
• W3211672278 hasAuthorship W3211672278A5014155213 @default.
• W3211672278 hasAuthorship W3211672278A5020464501 @default.
• W3211672278 hasAuthorship W3211672278A5020831161 @default.
• W3211672278 hasAuthorship W3211672278A5028823803 @default.
• W3211672278 hasAuthorship W3211672278A5043529705 @default.
• W3211672278 hasAuthorship W3211672278A5046508238 @default.
• W3211672278 hasAuthorship W3211672278A5056645290 @default.
• W3211672278 hasAuthorship W3211672278A5059929672 @default.
• W3211672278 hasAuthorship W3211672278A5060246976 @default.
• W3211672278 hasAuthorship W3211672278A5071091495 @default.
• W3211672278 hasAuthorship W3211672278A5072180771 @default.
• W3211672278 hasBestOaLocation W32116722783 @default.
• W3211672278 hasConcept C121608353 @default.
• W3211672278 hasConcept C126322002 @default.
• W3211672278 hasConcept C143998085 @default.
• W3211672278 hasConcept C207103383 @default.
• W3211672278 hasConcept C2776694085 @default.
• W3211672278 hasConcept C2778424827 @default.
• W3211672278 hasConcept C2779438470 @default.
• W3211672278 hasConcept C2780739268 @default.
• W3211672278 hasConcept C2781182431 @default.
• W3211672278 hasConcept C44249647 @default.
• W3211672278 hasConcept C50382708 @default.
• W3211672278 hasConcept C71924100 @default.
• W3211672278 hasConceptScore W3211672278C121608353 @default.
• W3211672278 hasConceptScore W3211672278C126322002 @default.
• W3211672278 hasConceptScore W3211672278C143998085 @default.
• W3211672278 hasConceptScore W3211672278C207103383 @default.
• W3211672278 hasConceptScore W3211672278C2776694085 @default.
• W3211672278 hasConceptScore W3211672278C2778424827 @default.
• W3211672278 hasConceptScore W3211672278C2779438470 @default.
• W3211672278 hasConceptScore W3211672278C2780739268 @default.
• W3211672278 hasConceptScore W3211672278C2781182431 @default.
• W3211672278 hasConceptScore W3211672278C44249647 @default.
• W3211672278 hasConceptScore W3211672278C50382708 @default.
• W3211672278 hasConceptScore W3211672278C71924100 @default.
• W3211672278 hasFunder F4320322795 @default.
• W3211672278 hasFunder F4320322933 @default.
• W3211672278 hasIssue "2" @default.
• W3211672278 hasLocation W32116722781 @default.
• W3211672278 hasLocation W32116722782 @default.
• W3211672278 hasLocation W32116722783 @default.
• W3211672278 hasLocation W32116722784 @default.

• next